Description:

The recent developments in genetics research have led to an incredible growth in our understanding of ocular conditions, leading to the 2017 FDA approval of the first groundbreaking gene therapy and the ongoing development of new gene therapies for numerous inherited retinal dystrophies. Our increased understanding of the genetics of eye conditions expands the opportunities for eye care practitioners to provide patients with more specific diagnoses, more accurate assessment of prognoses, and improved counseling. This includes the ability to deliver gene-specific patient education on eligibility for gene therapy and gene therapy clinical trials.  This panel presentation and discussion will provide an introductory level overview of the most common patient questions and answers surrounding genetic testing and gene therapy. We will cover the current state of gene therapy as well as other ongoing clinical trials, including developments in CRISPR gene editing, optogenetics, and antisense oligonucleotide-based therapy. Focus will be placed on covering the information optometrists can provide to patients to help them make the best informed decisions about their ocular management. We will also discuss the ramifications of gene therapy for the future of low vision rehabilitation and ocular health management. Attendees will be provided with resources to stay up-to-date with genetics information and clinical trials.

Course Code:

AOA218-TD

Speaker(s):

Rachelle Lin, O.D.
rachelle.lin@gmail.com

Ben Shaberman, O.D.
bshaberman@fightingblindness.org

Jill Dolgin, PharmD
jdolgin@agtc.com

Credits:

2

AOA Expiration Date:

3/3/2025

Related News

AOA-PAC election report: Optometry has outsized impact on 2024 elections

Tap into the AOA’s interactive 2024 elections map to see how hundreds of pro-optometry U.S. House and Senate candidates fared and learn how advocates can get more involved in the fight in our nation’s capital for patients and the future of the profession.

New AOA clinical guideline puts focus on elevating care of glaucoma patients

Guideline provides list of evidence- and consensus-based recommendations for care of primary open-angle glaucoma, the most common type of glaucoma. How many of these recommendations do you follow?

Introducing the new CMS G2211 code

In certain cases, this new code can be used for Medicare claims. Here’s how it works.